Clinical Trials - CLOSED PROTOCOLS 

 

CECOG performs high-quality clinical trials in Oncology.
For criteria for qualification of centers including requirements defined by Good Clinical Practice, please send an e-mail to cecog@cecog.at

 

The following protocols are closed for patient enrollment:

Colorectal Cancer

• CECOG/CORE.1.2.001
  
  A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX 6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer.
  

Pancreatic Cancer

• CECOG/PAN 1.3.001, SAKK 44/00

  Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial.
  SAKK 44/00
  

Breast Cancer

• CECOG/BREAST.2.2.005

  A Randomized Phase II Study of Dose-Dense Fluorouracil plus Epirubicin75 plus Cyclophosphamide (FEC75) and Fluorouracil plus Epirubicin90 plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer
  
  
• CECOG/BC.1.3.002
  
  A Randomized Phase III Study Comparing Concomitant Docetaxel plus Gemcitabine to Sequential Therapy of Docetaxel followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients.
  Area: Central- and Southeastern Europe, Israel and Lebanon
  
  
• CECOG/GBG
  
  Eine multizentrische Studie der Phase III zum Vergleich von Capecitabin alleine oder in Kombination mit Trastuzumab bei Patientinnen mit HER2 positiver metastasierter Brustkrebserkrankung und Progression nach vorheriger Behandlung mit Trastuzumab (Behandlung nach Progression).

  A multicenter randomized phase III study to compare capecitabine alone versus capecitabine with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with taxanes and trastuzumab (Treatment Beyond Progression, TBP).

  Area: An intergroup trial with the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) "Metastasiertes Mammakarzinom", Germany.

• Phase III Study of Gemcitabine/Epirubicin/Paclitaxel Combination versus Standard 5-Fluorouracil/Epirubicin/Cyclophosphamide Combination as First Line Chemotherapy in Metastatic Breast Cancer: GET versus FEC
  (CECOG-BM1)

  Area: Central- and Southeastern Europe and Israel
  Published in: Proc. Am. Soc. Clin. Oncol. 25:26, 2003 and J. Clin. Oncol. 2005 Mar 1; 23(7):1401-8

Esophago-Gastric Cancer

• CECOG/ESGAS 1.2.001
  
  Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally recurrent esophagogastric cancer previously untreated with chemotherapy for advanced disease
  
  Area: Austria
  
  
• CECOG/ESGAS 1.2.002
  
  A Phase II Study of Irinotecan, mitomycin C and capecitabine as second line chemotherapy for patients with metastatic or locally recurrent esophago-gastric cancer previously treated with chemotherapy for advanced disease.
  
  Area: Austria
  
  
  

Non Small Cell Lung Cancer

• CECOG is participating in the ALIMTA - H3E-MC-JMEN Trial
  
  A phase III, double-blinded, placebo-controlled study of Pemetrexed plus best supportive care vs. best supportive care as maintenance therapy immediately following induction treatment for advanced Non-Small Cell Lung Cancer.
  
  
• CECOG/NSCLC.3.2.002
  
  A Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo- Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer
  
  Area: Austria, Hungary, Poland
  

• Gemtax III

  Phase III comparing first line combination therapy versus sequential chemotherapy with Docetaxel and Gemcitabine in advanced Non Small Cell Lung Cancer (NSCLC)
  A cooperation with the Thoraxklinik Heidelberg, Germany.

• CECOG/NSCLC.2.2.001

  An open, randomized, multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the adjuvant treatment of Non-Small Cell Lung Cancer (NSCLC)
  Stage I-II
  Area: Austria and Hungary
  

• Gemcitabine and Cisplatin With and Without Subsequent Maintenance Therapy with Single Agent Gemcitabine in Stage IV Non-small Cell Lung Cancer. A Randomized, Multicentric Study
  (CECOG-NSCLC1)

  Area: Central- and Southeastern Europe and Israel
  Published in: Lung Cancer 41, Suppl. 2:O-88, 203 and Lung Cancer 2006 May; 52(2):155-63

Gastrointestinal Stromal Tumours

• CECOG/GIST 1.2.001
  
  Open-label Trial of Glivec in Patients with Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing c-kit
  
  Area: Austria, Bosnia, Bulgaria, Croatia, Czech Republic, Latvia, Lithuania, Romania, Slovenia, Slovakia, Yugoslavia/Serbia
  
  
• GIST 1.2.002 Molecular Substudy
  
  Molecular mechanisms associated with response/resistance to Glivec in patients with unresectable or metastatic malignant gastrointestinal stromal tumur expressing c-kit.
  
  Area: same as CECOG/GIST.1.2.001
  
  

Prostate Cancer

• CECOG/PROSTATE 1.2.001
  
  A randomised open-label (ZOMETA^® + hormonal ablation vs. hormonal ablation alone) multicenter prospective clinical study to show the efficacy of intravenous ZOMETA^® (zoledronic acid) 4 mg for prevention of bone metastases in hormone-naïve high risk patients with locally advanced prostate cancer.
  
  Area: Austria, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Russia, Slovakia, Slovenia, South Africa, Yugoslavia.
  
  

For further information on inclusion and exclusion criteria, dosages and schedules as well as other necessary information, please send an e-mail to
cecog@cecog.at

 top